Lenacapavir Sodium Patent Expiration

Lenacapavir Sodium is Used for treating HIV-1 infection with multidrug resistance in heavily treatment-experienced adults when combined with other antiretrovirals. It was first introduced by Gilead Sciences Inc in its drug Sunlenca on Dec 22, 2022.


Lenacapavir Sodium Patents

Given below is the list of patents protecting Lenacapavir Sodium, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Sunlenca US10071985 Therapeutic compounds Aug 17, 2037 Gilead Sciences Inc
Sunlenca US10654827 Therapeutic compounds Aug 17, 2037 Gilead Sciences Inc
Sunlenca US11267799 Solid forms of an HIV capsid inhibitor Aug 16, 2038 Gilead Sciences Inc
Sunlenca US11944611 Capsid inhibitors for the treatment of HIV Jun 04, 2041 Gilead Sciences Inc
Sunlenca US11944611 Capsid inhibitors for the treatment of HIV Jun 04, 2041 Gilead Sciences Inc
Sunlenca US9951043 Therapeutic compounds Feb 28, 2034 Gilead Sciences Inc


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Lenacapavir Sodium's patents.

Given below is the list recent legal activities going on the following patents of Lenacapavir Sodium.

Event Date Patent/Publication
Patent litigations
Electronic Review 07 Jun, 2024 US11944611
Petition Entered 30 May, 2024 US11944611
Second letter to regulating agency to determine regulatory review period 10 May, 2024 US9951043
Recordation of Patent eGrant 02 Apr, 2024 US11944611
Recordation of Patent Grant Mailed 02 Apr, 2024 US11944611
Patent Issue Date Used in PTA Calculation 02 Apr, 2024 US11944611
Patent eGrant Notification 02 Apr, 2024 US11944611
Email Notification 02 Apr, 2024 US11944611
Mail Patent eGrant Notification 02 Apr, 2024 US11944611
Email Notification 14 Mar, 2024 US11944611



Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳